Angelica Petrillo: Recently published key meta-analyses about ICIs in gastric cancer
Angelica Petrillo, Medical Doctor at Ospedale del Mare Napoli, shared a post by Arndt Vogel on X, about recent paper published in ESMO Open, adding:
Authors: A. G. Leone, A. S. Mai, K. Y. Fong, D. W. T. Yap, K. Kato, E. Smyth, M. Moehler, J. T. C. Seong, Raghav Sundar, Joseph J. Zhao, Filippo Pietrantonio.
”Recently published key meta-analyses about ICIs (immune checkpoint inhibitors) in gastric cancer according to PD-L1 (programmed death-ligand 1) by Lizzy Smyth, Filippo Pietrantonio, Raghav Sundar, Joseph J. Zhao. Definitely to read and apply in clinical practice.”
Quoting Arndt Vogel‘s post:
”Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different PD-L1 (programmed death-ligand 1) subgroups.
- Only very modest benefit in PD-L1 low HER-2 (human epidermal growth factor receptor 2) negative GEAC (gastroesophageal adenocarcinoma).
- Olbetuximab better alternative in Claudin18.2 positive tumors.”
Arndt Vogel, MD, is a Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. Leading the GI-Cancer Center and the Center for Personalized Medicine, his research focuses on translational and clinical studies in gastrointestinal cancer. He’s actively engaged in various societies including ESMO, ASCO, and EASL. Additionally, he chairs the Hepatobiliary Cancer Study Group of the AIO, contributing significantly to clinical oncology in Germany. Within ESMO, he serves on the Guidelines Steering Committee.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023